Prostate cancer screening: What we have learned from the PLCO and ERSPC trials

Jeffrey La Rochelle, Christopher L. Amling

Research output: Contribution to journalShort surveypeer-review

12 Scopus citations


Two large randomized trials on prostate cancer screening have recently reported their 10-year results with somewhat differing conclusions. The Prostate, Lung, Colorectal, and Ovarian Cancer Screening (PLCO) study found a slightly higher risk of a prostate cancer diagnosis in the screening cohort, but no cancer-specific survival advantage was seen for this group. However, the study had widespread screening contamination in the control arm that significantly weakens the study's ability to reach a valid conclusion about the benefits of screening. The European Randomized Study of Screening in Prostate Cancer (ERSPC) was less affected by screening contamination of the control arm, and a cancer-specific survival benefit for the screening arm was seen by 7-8 years (RR, 0.70-0.80). Based on these studies, it is reasonable to conclude that there is a survival benefit for screening, but it may not extend to older men (>75 years) who have undergone prior screening.

Original languageEnglish (US)
Pages (from-to)198-201
Number of pages4
JournalCurrent urology reports
Issue number3
StatePublished - May 1 2010


  • Prostate cancer
  • Prostate-specific antigen
  • Randomized studies
  • Screening

ASJC Scopus subject areas

  • Urology


Dive into the research topics of 'Prostate cancer screening: What we have learned from the PLCO and ERSPC trials'. Together they form a unique fingerprint.

Cite this